AQR Capital Management
OLMA icon

AQR Capital Management’s Olema Pharmaceuticals OLMA Stock Holding History

AQR Capital Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
89,562
+8,395
+10% +$187K ﹤0.01% 2616
2025
Q4 		$2.03M Sell
81,167
-14
-0% -$249 ﹤0.01% 2123
2025
Q3 		$795K Sell
81,181
-1,694
-2% -$10.2K ﹤0.01% 2566
2025
Q2 		$353K Buy
82,875
+37,214
+82% +$166K ﹤0.01% 2778
2025
Q1 		$172K Buy
+45,661
New +$230K ﹤0.01% 2921
2024
Q3 		– Sell
-12,125
Closed -$131K – 2844
2024
Q2 		$131K Buy
12,125
+704
+6% +$7.63K ﹤0.01% 2470
2024
Q1 		$129K Buy
11,421
+640
+6% +$8.26K ﹤0.01% 2313
2023
Q4 		$151K Buy
10,781
+728
+7% +$9.78K ﹤0.01% 2247
2023
Q3 		$124K Buy
+10,053
New +$102K ﹤0.01% 2204
2022
Q3 		– Sell
-70,973
Closed -$289K – 2280
2022
Q2 		$289K Buy
70,973
+29,457
+71% +$93.4K ﹤0.01% 1874
2022
Q1 		$177K Buy
+41,516
New +$229K ﹤0.01% 2086

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

AQR Capital Management's OLMA Position: Q1 2026 in Review

AQR Capital Management increased its Olema Pharmaceuticals (OLMA) stake by 10% in Q1 2026, buying an estimated $187K and bringing the position to 89,562 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

AQR Capital Management first reported a position in OLMA in Q1 2022 and has held it in 11 quarters since. The position peaked at $2.03M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • AQR Capital Management held 89,562 shares of Olema Pharmaceuticals worth $1.34M as of Q1 2026.
  • AQR Capital Management bought 8,395 Olema Pharmaceuticals shares in Q1 2026, an estimated $187K.
  • Olema Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2616 holding.
  • AQR Capital Management first reported a position in Olema Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
  • AQR Capital Management's Olema Pharmaceuticals position peaked at $2.03M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.